Privacy PolicyTerms of Service
OslerMarket
K
Ask OslerLibraryLearn
OslerMarket

Filtered resources

Clinical library

444 resources

Explore a topic. Choose a collection. Find your next resource.

444 resources
Clear filters

Collections 3

Cardiology: ACS & Heart Failure16 resourcesHypertension9 resourcesECG & More17 resources

Collections

3 of 45
  • Cardiology: ACS & Heart Failure16 resourcesACS by Labu Albert · MANAGEMENT OF ACUTE CORONARY SYNDROME …
  • Hypertension9 resources2025 AHA/ACC Guideline for the Management of High Blood Pressure in Adults · ESC 2024 Hypertension Guidelines …
  • ECG & More17 resourcesAN INTRODUCTION TO THE ECG and arrythmias revision ECG Oct 2025 (2) · LITTLE BLACK BOOK OF ECG SECRETS …

Resources

24 shown
MANAGEMENT OF CF/CCF coverClinical notesMANAGEMENT OF CF/CCFDr Norah Mwebaza·Cardiology· 3 pagesThis document provides a comprehensive overview of the management strategies for Congestive Cardiac Failure (CF/CCF), detailing various classes of medications and their therapeutic effects.
SESSION 10 coverClinical notesSESSION 10Cardiology· 8 pagesThis session includes questions related to the anatomy and physiology of the heart, focusing on ischemia, surgical considerations, and heart valve sounds.
HYPERTENSION MEDICATION TREATMENT PROTOCOL coverGuidelines & protocolsHYPERTENSION MEDICATION TREATMENT PROTOCOLCollege·Cardiology· 2 pagesThis document outlines a treatment protocol for hypertension in adults without certain comorbidities, providing a summary of antihypertensive medications and their dosing.
WHAT MAKES A META-ANALYSIS BELIEVABLE? coverClinical reviewsWHAT MAKES A META-ANALYSIS BELIEVABLE?Cedars-Sinai Medical Center, Yale School of Medicine, University of Glasgow·Cardiology· 2026· 4 pagesThis document discusses the credibility of meta-analyses, highlighting their influence on clinical practice and the importance of methodological rigor. It addresses the risks of overinterpretation and the necessity for a thorough risk-of-bias assessment.
ACETAZOLAMIDE AS A DECONGESTION STRATEGY IN ACUTE DECOMPENSATED HEART FAILURE: BALANCING FLUID REMOVAL AND ELECTROLYTE DISTURBANCES coverClinical reviewsACETAZOLAMIDE AS A DECONGESTION STRATEGY IN ACUTE DECOMPENSATED HEART FAILURE: BALANCING FLUID REMOVAL AND ELECTROLYTE DISTURBANCESKaiser Permanente San Francisco Medical Center·Cardiology· 10 pagesThis document discusses the use of acetazolamide as an adjunctive therapy for decongestion in patients with acute decompensated heart failure (ADHF), focusing on balancing fluid removal and electrolyte disturbances.
DYS LIPIDEMIA coverClinical reviewsDYS LIPIDEMIAJohns Hopkins University School of Medicine, Baltimore·Cardiology· 2023· 17 pagesDyslipidemia is an important risk factor for coronary artery disease and stroke, necessitating lifestyle interventions and lipid-lowering therapy for at-risk individuals.
THE NEW IN ANTICOAGULATION: FACTOR XI INHIBITORS coverClinical reviewsTHE NEW IN ANTICOAGULATION: FACTOR XI INHIBITORSFloraspe-Renzetti Hospital, ASL Lanciano-Vasto-Chieti; University of Pisa·Cardiology· 2023· 4 pagesThis document discusses the emerging role of factor XI inhibitors in anticoagulation therapy, highlighting their potential to reduce thrombotic risk with minimal bleeding complications. It reviews various pharmacological strategies currently under investigation.
CARDIOVASCULAR DISEASE: RISK ASSESSMENT AND REDUCTION, INCLUDING LIPID MODIFICATION coverGuidelines & protocolsCARDIOVASCULAR DISEASE: RISK ASSESSMENT AND REDUCTION, INCLUDING LIPID MODIFICATIONNational Institute for Health and Care Excellence (NICE)·Cardiology· 2023· 36 pagesThis clinical guideline provides recommendations for the assessment and reduction of cardiovascular disease risk, including lipid modification strategies.
RISK FOR BLEEDING-RELATED HOSPITALIZATIONS DURING USE OF AMIODARONE WITH APIXABAN OR RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION coverClinical reviewsRISK FOR BLEEDING-RELATED HOSPITALIZATIONS DURING USE OF AMIODARONE WITH APIXABAN OR RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATIONAnnals of Internal Medicine·Cardiology· 2023· 11 pagesThis study investigates the risk of bleeding-related hospitalizations in patients with atrial fibrillation receiving amiodarone alongside apixaban or rivaroxaban.
CARDIOPROTECTION IN PATIENTS AT HIGH RISK OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY coverClinical reviewsCARDIOPROTECTION IN PATIENTS AT HIGH RISK OF ANTHRACYCLINE-INDUCED CARDIOTOXICITYAmerican College of Cardiology Foundation·Cardiology· 2023· 6 pagesThis primer focuses on the evidence for cardioprotection strategies to mitigate anthracycline-related cardiotoxicity in high-risk patients. It discusses the potential for myocardial injury and heart failure associated with anthracycline treatment.
MODULATION AND PERSONALIZATION OF THERAPY AFTER ACUTE CORONARY SYNDROMES: THE ROAD TO PRECISION coverClinical reviewsMODULATION AND PERSONALIZATION OF THERAPY AFTER ACUTE CORONARY SYNDROMES: THE ROAD TO PRECISIONHeart Institute and Sorbonne University, National College of French Cardiologists, Sapienza University of Rome, Medical University of Lodz, Universita Cattolica de Sacro Cuore·Cardiology· 2023· 3 pagesThis document discusses the importance of modulating and personalizing therapy for patients after acute coronary syndromes (ACS) to improve outcomes. It highlights the need for tailored treatment strategies that consider individual patient characteristics.
SACUBITRIL/VALSARTAN IN THE TREATMENT OF RESISTANT HYPERTENSION: RAISING STAR OR ILLUSION? coverClinical reviewsSACUBITRIL/VALSARTAN IN THE TREATMENT OF RESISTANT HYPERTENSION: RAISING STAR OR ILLUSION?Klinik für Innere Medizin II, Cardiology Department, Universitätsklinikum Ulm; Department of Medicine and Surgery, University of Milano-Bicocca·Cardiology· 3 pagesThis editorial discusses the efficacy of sacubitril/valsartan in treating resistant hypertension, highlighting its potential benefits and limitations based on recent studies.
OPTIMAL DIURETIC STRATEGIES IN HEART FAILURE coverClinical reviewsOPTIMAL DIURETIC STRATEGIES IN HEART FAILUREUniversity of Alabama at Birmingham·Cardiology· 2021· 8 pagesThis review article discusses the optimal diuretic strategies for managing heart failure, focusing on the implications of various diuretics and their effects on patient outcomes.
HAEMODYNAMIC VALIDATION OF THE THREE-STEP HFA-PEFF ALGORITHM TO DIAGNOSE HEART FAILURE WITH PRESERVED EJECTION FRACTION coverClinical reviewsHAEMODYNAMIC VALIDATION OF THE THREE-STEP HFA-PEFF ALGORITHM TO DIAGNOSE HEART FAILURE WITH PRESERVED EJECTION FRACTIONDepartment of Management, Information and Production Engineering, University of Bergamo; Department of Cardiology, Istituto Auxologico Italiano IRCCS; Department of Clinical Sciences and Community Health, University of Milan; Department of·Cardiology· 2023· 8 pagesThis article presents the validation of the HFA-PEFF algorithm, a three-step approach for diagnosing heart failure with preserved ejection fraction (HFpEF). It evaluates the algorithm's effectiveness in determining the likelihood of HFpEF in patients.
INDIRECT TREATMENT COMPARISON BETWEEN FIXED-DOSE-COMBINATIONS OF AMLODIPINE/LOSARTAN AND AMLODIPINE/VALSARTAN IN BLOOD PRESSURE CONTROL coverClinical reviewsINDIRECT TREATMENT COMPARISON BETWEEN FIXED-DOSE-COMBINATIONS OF AMLODIPINE/LOSARTAN AND AMLODIPINE/VALSARTAN IN BLOOD PRESSURE CONTROLA. Lawrence Gould, S. Unniachan, D. Wu·Cardiology· 2013· 10 pagesThis study compared blood pressure changes after 8 weeks of therapy between a fixed-dose combination of amlodipine/losartan and amlodipine/valsartan using a network meta-analysis.
SIMULTANEOUS OR RAPID SEQUENCE INITIATION OF QUADRUPLE MEDICAL THERAPY FOR HEART FAILURE—OPTIMIZING THERAPY WITH THE NEED FOR SPEED coverClinical reviewsSIMULTANEOUS OR RAPID SEQUENCE INITIATION OF QUADRUPLE MEDICAL THERAPY FOR HEART FAILURE—OPTIMIZING THERAPY WITH THE NEED FOR SPEEDDuke Clinical Research Institute; Duke University School of Medicine; University of Mississippi Medical Center; Ahmanson-UCLA Cardiomyopathy Center·Cardiology· 2 pagesThis document discusses the importance of initiating quadruple medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) to improve survival rates and reduce hospitalization. It advocates for simultaneous or rapid sequence initiation of these therapies.
ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: WHAT DO THE CURRENT USPSTF GUIDELINES SAY? coverGuidelines & protocolsASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: WHAT DO THE CURRENT USPSTF GUIDELINES SAY?Department of Medicine, Hennepin Healthcare·Cardiology· 2022· 5 pagesThis document outlines the 2022 USPSTF guidelines regarding the use of aspirin for primary prevention of cardiovascular disease, emphasizing a case-by-case decision-making process for adults aged 40 to 59 with a significant 10-year CVD risk.
TIME TO QUADRUPLE GUIDELINE-DIRECTED MEDICAL THERAPY AS A KEY PERFORMANCE MEASURE FOR HEART FAILURE coverClinical reviewsTIME TO QUADRUPLE GUIDELINE-DIRECTED MEDICAL THERAPY AS A KEY PERFORMANCE MEASURE FOR HEART FAILUREnull·Cardiology· 4 pagesThis document discusses the importance of timely initiation of quadruple guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) as a quality metric.
Cardiovascular coverClinical toolsCardiovascularCardiology· 1 pagesA comprehensive checklist for performing a cardiovascular physical examination, covering inspection, palpation, percussion, auscultation, and peripheral vascular assessment.
Medly ECG Session 5 V RVH And LVH SMK 09.07.26 coverClinical notesMedly ECG Session 5 V RVH And LVH SMK 09.07.26Cardiology· 22 pages
Medly ECG Session 1 Introudction MSK 11.06.26 coverClinical notesMedly ECG Session 1 Introudction MSK 11.06.26Cardiology· 22 pages
Medly ECG Session 3 AXIS DETERMINATION DI 25.06.26 coverClinical notesMedly ECG Session 3 AXIS DETERMINATION DI 25.06.26Cardiology· 18 pages
Medly ECG Session 2 Rythm And Rate Determination JBN 18.06.26 coverClinical notesMedly ECG Session 2 Rythm And Rate Determination JBN 18.06.26Cardiology· 26 pages
Medly ECG Session 9 Revision II Common Pathologies In Heart Failure (NSTEMI, PE, STEMI) JBN 06.08.26 coverClinical reviewsMedly ECG Session 9 Revision II Common Pathologies In Heart Failure (NSTEMI, PE, STEMI) JBN 06.08.26Cardiology· 17 pages
PreviousPage 16 of 19Next

© 2026 Osler Market

Library·Ask Osler·Learn·Terms·Privacy·Support·WhatsApp Channel

For learning purposes. Always consult clinical guidelines.

Ask OslerLibraryLearn
HomeAskLibraryLearnAccount